30 minutes
Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating 'wet' in vitro/in vivo and 'dry' insilico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This panel will explore the new world of digital biology as a way to model potential drug effects more accurately and quickly.


Colin Hill - Chairman & CEO, GNS Healthcare
Juan Alvarez - AVP, Computational and Structural Chemistry, Merck Research Labs
Nora Khaldi - Founder & CSO, Nuritas
Rachel Hodos - Senior AI Scientist. BenevolentAI
Renée Deehan - PhD, VP, QuartzBio, Precision for Medicine
Name Audience
Science Track